Localized Prostate Cancer Treatment Algorithm

Opinion
Video

Rana R. McKay, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the treatment algorithm for patients with localized prostate cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Related Content
Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.

HLD-0915 Earns FDA Fast Track Designation in Metastatic CRPC

Roman Fabbricatore
August 15th 2025
Article
Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
August 15th 2025
Podcast
Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

INKmune Exhibits Favorable Safety in Metastatic CRPC

Roman Fabbricatore
August 15th 2025
Article
1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
August 15th 2025
Podcast
No dose-limiting toxicities or unexpected adverse effects occurred with carotuximab/apalutamide in metastatic castration-resistant prostate cancer.

Carotuximab/Apalutamide Shows Tolerability in Metastatic CRPC

Roman Fabbricatore
August 15th 2025
Article
More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

Tim Cortese
August 15th 2025
Article